Deceptive Advertising! Claims Novo in GLP-1 Lawsuit Fallout
Two pharmaceutical giants are in court over GLP-1 advertising. This tangle could redefine how GLP-1s are marketed and...
GLP-1
This tag page compiles 4 articles on GLP-1 trends, pricing, and weight-loss stock impacts, helping you understand how drug costs and market moves affect personal finances.
50 articlesCathie Wood Loading This GLP-1 Stock: What It Means for Investors
A high-profile investor move has eyes turning to a GLP-1 stock with big growth potential. Here’s what it means for ri...
Wegovy Pill Just Changed: Why Lilly Stock Could Still Win
A new oral Wegovy launch is reshaping GLP-1 dynamics. Even with Novo Nordisk gaining ground, Eli Lilly stock could st...
Prediction: New Reason Lilly Stock Could Still Rise
Eli Lilly stock could advance in the second half of 2026 as Foundayo gains traction and the GLP-1 franchise shines, b...
Lilly’s $400 Billion Surge Reshapes Big Pharma, Rally
Eli Lilly has added roughly $400 billion in market value over the past year, fueling a dramatic shift in Big Pharma a...
Two Drugmakers Dominate Obesity Boom, Tiny Fund Holds Both
Two drugmakers lead the obesity drug surge, while a small fund owns both names at a fractional stake. This highlights...
Wall Street Bets Lilly’s GLP-1 Portfolio, Missed $1T
Investors are placing massive bets on Eli Lilly’s GLP-1 drugs, but the push for a $1 trillion opportunity faces medic...
Lilly Novo Nordisk Fine: Two Stocks Riding GLP-1 Boom
The GLP-1 wave has traders buzzing. While Lilly and Novo Nordisk hold steady as reliable bets, smart portfolios tap i...
Late Lilly Stock? Here's What $1,000 Could Become in 10 Years
If you’re wondering whether Eli Lilly stock still has room to run, you’re not alone. This guide outlines scenarios fo...
Johnson Johnson Walking Away Could Boost Long-Term Value
Johnson Johnson walking away from a GLP-1 obesity obsession signals a shift to a diversified, potentially more resili...
Lilly Price Prediction: Case for Double-Digit Upside
Eli Lilly faces a pivotal year as its GLP-1 franchise powers revenue growth and new oral therapies expand addressable...
Pfizer Could Prove Underrated GLP-1 Stock Opportunity
Pfizer may be sitting on a hidden GLP-1 opportunity. This article breaks down why the company could prove to be an un...